Change in board of directors of Qlife Holding AB

Qlife Holding AB (“Qlife”) today announces that the board member Mette-Marie Harild has resigned from the board of directors on her own initiative.

Pursuant to Qlife’s articles of association, the board of directors shall be comprised of not less than three and not more than eight board members. After Mette-Marie Harild’s resignation, the board of directors will be comprised of four members and thus the requirements in the articles of association are met Furthermore, the board of directors retains a quorum.

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 2023-08-02 13:30 CET.

For more information please contact:

Thomas Warthoe, CEO
+45 21 63 35 34

Qlife is a medical device company born to challenge the status quo in healthcare. We work to shift the perspective and turn today’s view on healthcare into tomorrow’s focus on health- empowerment. We are on a quest to empower people with more accessible ways to understand their health – so that they can move beyond reactive care towards proactive wellbeing. It’s how we contribute to improving quality of life for every individual and for the greater society.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor.
Read more on, or follow us on LinkedIn.